EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel

Bailey M Tibben iD, David W Hein iD, Michelle Whirl-Carrillo iD, Andrea Gaedigk iD, Michael T Eadon iD, Rodney F Minchin iD, Sotiria Boukouvala iD, Adalberto Rezende Santos iD, Roseann S Donnelly iD, José A G Agúndez iD, Kelly E Caudle iD

Clinical Pharmacology & Therapeutics · 2026-10 · 120 (4) · 1101-1110

DOI: 10.1002/cpt.70420 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, online erschienen am 31.07.2026. Verfasst von Bailey M Tibben und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Arylamine N-Acetyltransferase, Pharmacogenetics. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

NAT2 encodes arylamine N‐acetyltransferase 2, a key enzyme in the phase II metabolism of arylamines and arylhydrazines. NAT2 is highly polymorphic, resulting in variable distributions of rapid and poor metabolizers across global populations. Here, we detail the process undertaken by the Clinical Pharmacogenetics Implementation Consortium (CPIC) NAT2 Pharmacogene Curation Expert Panel (PCEP) to assign clinical function to NAT2 star (*) alleles using CPIC's standard terminology. Given the observed impact of NAT2 genetic variability on drug response, CPIC convened the NAT2 ‐PCEP to standardize clinical allele function assignments. The NAT2 ‐PCEP is comprised of multidisciplinary and international members, including researchers, clinicians, and implementers with expertise in pharmacogenomics and NAT2 molecular biology. Extensive in vitro and clinical literature was curated from PubMed and other sources to assess NAT2 genotype‐to‐phenotype concordance as well as the biochemical function of NAT2 star alleles. The NAT2 ‐PCEP assigned allele clinical function using CPIC's standard terminology (increased, decreased, uncertain, and unknown function) to 59 star alleles cataloged by the Pharmacogene Variation Consortium (PharmVar). Two alleles, NAT2*1 and NAT2*4 , were assigned increased function (historically known as rapid), 40 alleles were assigned decreased function (historically known as slow), 10 alleles were assigned uncertain function, and seven alleles were assigned unknown function. Rigorous evidence review and in‐depth PCEP discussion were crucial in determining these function assignments. The findings reported here underscore the importance of standardized allele functional terms and diplotype‐to‐phenotype assignments to further the clinical implementation of NAT2 pharmacogenetic test results.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arylamine N-AcetyltransferasePharmacogeneticsHumansAllelesPhenotype

Substanzen

Arylamine N-AcetyltransferaseNAT2 protein, human

Autor:innen und Institutionen

  • Department of Pharmacy and Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
  • Department of Pharmacology and Toxicology, University of Louisville School of Medicine, Louisville, Kentucky, USA.
  • Department of Biomedical Data Science, Stanford University, Stanford, California, USA.
  • Division of Clinical Pharmacology, Toxicology and Therapeutic Innovation, Children's Mercy Kansas City, Kansas City, Missouri, USA.
  • School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Bailey M Tibben, David W Hein, Michelle Whirl-Carrillo, Andrea Gaedigk, Michael T Eadon, Rodney F Minchin, Sotiria Boukouvala, Adalberto Rezende Santos, Roseann S Donnelly, José A G Agúndez, Kelly E Caudle

Zitieren

APA

Tibben, B. M., Hein, D. W., Whirl-Carrillo, M., Gaedigk, A., Eadon, M. T., Minchin, R. F., Boukouvala, S., Santos, A. R., Donnelly, R. S., Agúndez, J. A. G., & Caudle, K. E. (2026). Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel. Clinical Pharmacology & Therapeutics, 120(4), 1101-1110. https://doi.org/10.1002/cpt.70420

Vancouver

Tibben BM, Hein DW, Whirl-Carrillo M, Gaedigk A, Eadon MT, Minchin RF, et al. Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel. Clinical Pharmacology & Therapeutics. 2026;120(4):1101-1110. doi:10.1002/cpt.70420

BibTeX
@article{Tibben2026,
  author = {Tibben, Bailey M and Hein, David W and Whirl-Carrillo, Michelle and Gaedigk, Andrea and Eadon, Michael T and Minchin, Rodney F and Boukouvala, Sotiria and Santos, Adalberto Rezende and Donnelly, Roseann S and Agúndez, José A G and Caudle, Kelly E},
  title = {Clinical Function Assignment of NAT2 Alleles by the Clinical Pharmacogenetics Implementation Consortium Pharmacogene Curation Expert Panel},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2026},
  volume = {120},
  number = {4},
  pages = {1101--1110},
  doi = {10.1002/cpt.70420}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche